<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03012594</url>
  </required_header>
  <id_info>
    <org_study_id>HS16-0465</org_study_id>
    <nct_id>NCT03012594</nct_id>
  </id_info>
  <brief_title>Lanreotide in the Treatment of Small Bowel Motility Disorders</brief_title>
  <official_title>A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a human research study looking at the effectiveness of Lanreotide (study medication)
      in treating small bowel motility disorders. It is similar to a natural hormone somatostatin
      that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a
      growth hormone-inhibiting hormone. Lanreotide is a man made hormone and is a long acting
      medication that is given once a month. It is marketed with a trade name &quot;Somatuline Depot&quot;.
      It is given deep subcutaneously (deep within the layers of the skin) in the superior external
      quadrant of the buttock. Injection site will be alternated on subsequent injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that in patients with small bowel motility disorders,
      Lanreotide helps in alleviating the symptoms. Lanreotide is an FDA approved medication for
      management of acromegaly and neuroendocrine tumors, but has never been used for treating
      small bowel motility disorders. However, Octreotide which is similar to Lanreotide but is a
      short acting synthetic somatostatin has been used in few research studies.

      If a patient is interested and qualifies for the study then he/she will be explained about
      the study and signature will be collected on the consent form. Health and social history will
      be collected. Blood work, urine analysis, pregnancy test (in women of reproductive age group
      and have the capability of getting pregnant)) will be performed to make sure that patient
      qualifies for the study and for follow-up during the treatment. Physical examination, ECG,
      wireless motility capsule testing and hydrogen breath testing will be performed. Patients
      will be required to complete a questionnaire regarding their health.

      The total study duration from the first administration of study drug is 12 weeks. The study
      medication will be given once a month for 3 months and there is a 1 month follow-up after the
      last study medication. There will be a screening visit approximately 1 month before the first
      study drug administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of lanreotide on small bowel motility disorders as measured by small bowel transit time</measure>
    <time_frame>3 months</time_frame>
    <description>If the small bowel transit time, as measured by wireless capsule endoscopy, is decreased to &lt; 6hrs, then patient would be considered a responder and that lanreotide is efficacious.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement in symptoms assessed by improvement in upper gastrointestinal disorders-symptom severity index (PAGI-SYM) scores. (PAGI-SYM is a brief (20-items with 6 sub scales) symptom severity questionnaire that captures information on common upper gastrointestinal symptoms, including heartburn, regurgitation, fullness, early satiety, bloating, nausea and vomiting, and upper abdominal pain). If the PAGI-Sym scores were decreased by at least 0.7 points compared to pre treatment, then it will be considered that lanreotide has significantly improved the symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of small intestinal bacterial overgrowth</measure>
    <time_frame>3 months</time_frame>
    <description>Resolution of small intestinal bacterial overgrowth as assessed by hydrogen breath testing. If the hydrogen breath test is positive (&gt;20 ppm from the baseline) before treatment and it decreases (changes to &lt;20 from the baseline) after treatment, it will be considered that lanreotide is efficacious in decreasing the small intestinal bacterial overgrowth.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastrointestinal Motility Disorder</condition>
  <condition>Intestinal Disease</condition>
  <arm_group>
    <arm_group_label>Lanreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <description>Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart</description>
    <arm_group_label>Lanreotide</arm_group_label>
    <other_name>Somatuline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consecutive patients with evidence of small bowel motility disorders, referred to (or)
             are patients of the Gastroenterology and Motility Center at Northwell Health System.

          2. Aged between 18 and 70 years.

          3. Subjects should be capable of understanding the study and be able to give informed
             consent.

          4. Patient having small bowel motility disorder as evidenced by delayed small bowel
             transit by wireless motility capsule (WMC) testing to &gt; 6 hours.

          5. To participate in the study, patients will have to stop taking Octreotide (because it
             has the same mechanism of action as the study medication) if theyare currently taking
             it; it should be stopped for at least 4 weeks before taking the first dose of this
             study medication.

        General Exclusion Criteria

          1. Age &lt;18 or age &gt;70

          2. Pregnancy as assessed by urine pregnancy test.

        Exclusion Criteria for performing wireless motility capsule testing

          1. History of gastric bezoar

          2. History of Disorders of swallowing

          3. Known or suspected small bowel diverticula, diverticulitis, strictures, fistulas,
             Crohn's disease, or any other relevant medical comorbidity (e.g. chronic alcohol
             abuse)

          4. Prior intestinal surgery, including IC valve resection or gastrointestinal surgeries
             that create a blind loop (e.g. Bilroth II or Roux-en-Y)

          5. History of Severe dysphagia to food or pills

          6. A participant who uses an implanted or portable electro-mechanical medical device such
             as a cardiac pacemaker or infusion pump

          7. Inability to be off intestinal transit altering medication for at least one week (e.g.
             opiates, laxatives, etc.)

          8. Any person unable or unwilling to undergo abdominal surgery.

          9. BMI &gt; 40.

        Exclusion Criteria due to Lanreotide

          1. Current use or recent (within last 7 days) use of acid suppressive therapy, prokinetic
             agents, laxatives, and opiates, or other agents known to affect gastrointestinal
             motility.

          2. Disorders associated with presumed small intestinal motility disorders including:
             scleroderma, intestinal pseudo-obstruction, and autonomic visceral neuropathy (e.g.
             longstanding diabetes of more than 20 years and/or poorly controlled diabetes (glucose
             &gt; 250, glycosylated hemoglobin (HbA1c) &gt; 8.5%)

          3. Current use of cyclosporine (Gengraf, Neoral, or Sandimmune), a medicine called
             bromocriptine (Parlodel, Cycloset), or medicines that lower heart rate, such as beta
             blockers.

          4. Cardiac arrhythmia based on health history (palpitations, feeling a pause between
             heartbeats, lightheadedness, passing out, shortness of breath, or chest pain).

             Bradycardia and Tachycardia are monitored during every visit to the clinic, using
             pulse rate.

             ECG will be performed during screening visit and during 8th week of the study. The
             following are accessed with ECG.

               -  Bradycardia &lt;60 beats/min.

               -  Tachycardia &gt;100 beats/min.

               -  Atrial Fibrillation - Rapid irregular atrial signal with no real P-waves and
                  irregular ventricular rate.

               -  Ventricular Fibrillation - Irregular ventricular waveforms.

               -  Sinus Arrhythmia - Normal beats, but triggered at an irregular interval from 60
                  to 100 BPM, causing varying R-R interval.

               -  Missed beats.

          5. Chronic kidney disease (moderate and severe renal impairment as calculated by
             creatinine clearance of &lt;50 mL/min)

          6. Hepatic Impairment - Subjects with Child-Pugh Class B and Class C.

          7. Significant electrolyte abnormalities: Anything outside of the normal range by +/- 20
             % will be considered as abnormal.

          8. Cholilithiasis (Total bilirubin &gt;2x of normal)

          9. Pancreatitis

         10. Hepatitis (AST, ALT or Alk Ph, greater than upper limit of normal(ULN), Serum albumin
             &lt;3.0 g/dL unless prothrombin time is within the normal range)

         11. Present cholecystitis

         12. Uncontrolled congestive heart failure

         13. Known hypersensitivity to the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bani Roland, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bani Roland, M.D.</last_name>
    <phone>(212) 434 - 1850</phone>
    <email>broland@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anil Vegesna</last_name>
    <phone>(516) 562-0334</phone>
    <email>avegesna@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bani Roland, MD</last_name>
      <phone>212-434-6274</phone>
      <email>broland@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bani Roland, MD</last_name>
      <phone>212-434-6274</phone>
      <email>broland@northwell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991 Nov 21;325(21):1461-7.</citation>
    <PMID>1944424</PMID>
  </reference>
  <reference>
    <citation>Owyang C. Octreotide in gastrointestinal motility disorders. Gut. 1994;35(3 Suppl):S11-4. Review.</citation>
    <PMID>8206395</PMID>
  </reference>
  <reference>
    <citation>Edmunds MC, Chen JD, Soykan I, Lin Z, McCallum RW. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998 Feb;12(2):167-74.</citation>
    <PMID>9692691</PMID>
  </reference>
  <reference>
    <citation>Faure C, Goulet O, Ategbo S, Breton A, Tounian P, Ginies JL, Roquelaure B, Despres C, Scaillon M, Maurage C, Paquot I, Hermier M, De Napoli S, Dabadie A, Huet F, Baudon JJ, Larchet M. Chronic intestinal pseudoobstruction syndrome: clinical analysis, outcome, and prognosis in 105 children. French-Speaking Group of Pediatric Gastroenterology. Dig Dis Sci. 1999 May;44(5):953-9.</citation>
    <PMID>10235603</PMID>
  </reference>
  <reference>
    <citation>Stanghellini V, Cogliandro RF, de Giorgio R, Barbara G, Salvioli B, Corinaldesi R. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil. 2007 Jun;19(6):440-52. Review.</citation>
    <PMID>17564625</PMID>
  </reference>
  <reference>
    <citation>Mann SD, Debinski HS, Kamm MA. Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults. Gut. 1997 Nov;41(5):675-81.</citation>
    <PMID>9414977</PMID>
  </reference>
  <reference>
    <citation>Lybaert W. The use of lanreotide autogelÂ® in the treatment of intestinal obstruction in a patient with adenocarcinoma. Case Rep Oncol. 2014 Jan 16;7(1):43-6. doi: 10.1159/000358124. eCollection 2014 Jan.</citation>
    <PMID>24575015</PMID>
  </reference>
  <reference>
    <citation>Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol. 1997 Jan;43(1):65-70.</citation>
    <PMID>9056054</PMID>
  </reference>
  <reference>
    <citation>Camilleri M. Small bowel motility disorders. Rev Gastroenterol Mex. 1994 Apr-Jun;59(2):120-6.</citation>
    <PMID>7991964</PMID>
  </reference>
  <reference>
    <citation>Wang C, Xu H, Chen H, Li J, Zhang B, Tang C, Ghishan FK. Somatostatin stimulates intestinal NHE8 expression via p38 MAPK pathway. Am J Physiol Cell Physiol. 2011 Feb;300(2):C375-82. doi: 10.1152/ajpcell.00421.2010. Epub 2010 Nov 24.</citation>
    <PMID>21106692</PMID>
  </reference>
  <reference>
    <citation>Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8. doi: 10.1210/jc.2009-2670. Epub 2010 Apr 21.</citation>
    <PMID>20410227</PMID>
  </reference>
  <reference>
    <citation>Wyrwich KW, Mody R, Larsen LM, Lee M, Harnam N, Revicki DA. Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants. Qual Life Res. 2010 May;19(4):551-64. doi: 10.1007/s11136-010-9620-x. Epub 2010 Feb 27.</citation>
    <PMID>20195905</PMID>
  </reference>
  <reference>
    <citation>Revicki DA, Rentz AM, Tack J, Stanghellini V, Talley NJ, Kahrilas P, De La Loge C, Trudeau E, Dubois D. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol. 2004 Sep;2(9):769-77.</citation>
    <PMID>15354277</PMID>
  </reference>
  <reference>
    <citation>Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, Trudeau E, Dubois D, Revicki DA. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004 Dec;13(10):1737-49.</citation>
    <PMID>15651544</PMID>
  </reference>
  <reference>
    <citation>De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut. 2004 Nov;53(11):1549-52. Review.</citation>
    <PMID>15479666</PMID>
  </reference>
  <reference>
    <citation>Iida H, Ohkubo H, Inamori M, Nakajima A, Sato H. Epidemiology and clinical experience of chronic intestinal pseudo-obstruction in Japan: a nationwide epidemiologic survey. J Epidemiol. 2013;23(4):288-94.</citation>
    <PMID>23831693</PMID>
  </reference>
  <reference>
    <citation>Goulet O, Sauvat F, Jan D. Surgery for pediatric patients with chronic intestinal pseudo-obstruction syndrome. J Pediatr Gastroenterol Nutr. 2005 Sep;41 Suppl 1:S66-8.</citation>
    <PMID>16131977</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Bani Chander Roland</investigator_full_name>
    <investigator_title>Director of Gastrointestinal Motility</investigator_title>
  </responsible_party>
  <keyword>Small bowel motility disorder</keyword>
  <keyword>Slow intestinal motility</keyword>
  <keyword>Small bowel bacterial overgrowth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

